JP2019525955A - 新規化合物およびその使用 - Google Patents
新規化合物およびその使用 Download PDFInfo
- Publication number
- JP2019525955A JP2019525955A JP2019522609A JP2019522609A JP2019525955A JP 2019525955 A JP2019525955 A JP 2019525955A JP 2019522609 A JP2019522609 A JP 2019522609A JP 2019522609 A JP2019522609 A JP 2019522609A JP 2019525955 A JP2019525955 A JP 2019525955A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- compound according
- hydroxy
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662361263P | 2016-07-12 | 2016-07-12 | |
| US62/361,263 | 2016-07-12 | ||
| PCT/US2017/041526 WO2018013559A1 (en) | 2016-07-12 | 2017-07-11 | Novel compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019525955A true JP2019525955A (ja) | 2019-09-12 |
| JP2019525955A5 JP2019525955A5 (https=) | 2020-08-20 |
Family
ID=60942054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522609A Pending JP2019525955A (ja) | 2016-07-12 | 2017-07-11 | 新規化合物およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9944632B2 (https=) |
| EP (1) | EP3368011A4 (https=) |
| JP (1) | JP2019525955A (https=) |
| KR (1) | KR20190039125A (https=) |
| CN (2) | CN108495618B (https=) |
| AU (1) | AU2017297344A1 (https=) |
| CA (1) | CA3030411A1 (https=) |
| HK (1) | HK1257296A1 (https=) |
| MA (1) | MA43141A (https=) |
| WO (1) | WO2018013559A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108495618B (zh) | 2016-07-12 | 2019-08-16 | 冰洲石生物科技公司 | 新的化合物及其用途 |
| US20220016102A1 (en) * | 2018-11-21 | 2022-01-20 | Shanghaitech University | Er protein regulators and use thereof |
| SG11202105256QA (en) | 2018-11-21 | 2021-06-29 | Accutar Biotechnology Inc | Novel compounds having estrogen receptor alpha degradation activity and uses thereof |
| CN113614076A (zh) * | 2019-01-03 | 2021-11-05 | 密执安大学评议会 | 雌激素受体蛋白降解剂 |
| CN112390852B (zh) * | 2019-08-14 | 2022-10-18 | 上海济煜医药科技有限公司 | 作为蛋白降解剂的化合物及其制备方法和应用 |
| EP3835298B1 (en) * | 2019-12-12 | 2024-06-26 | Accutar Biotechnology Inc. | Novel chroman derivatives having estrogen receptor degradation activity and uses thereof |
| JP2023508357A (ja) * | 2019-12-23 | 2023-03-02 | アキュター バイオテクノロジー インコーポレイテッド | エストロゲン受容体分解剤とサイクリン依存性キナーゼ阻害剤との癌治療用組み合わせ |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013056837A (ja) * | 2011-09-07 | 2013-03-28 | Japan Health Science Foundation | アポトーシス阻害タンパク質リガンド−エストロゲン受容体リガンドハイブリッド化合物並びにそれを利用したエストロゲン受容体分解誘導剤及び乳癌、子宮頚癌又は卵巣癌の予防及び治療剤 |
| US20160136230A1 (en) * | 2013-07-03 | 2016-05-19 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681835A (en) * | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| KR102668696B1 (ko) * | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2014008159A1 (en) * | 2012-07-03 | 2014-01-09 | The University Of North Carolina At Chapel Hill | Selective estrogen receptor degraders for treatment of tamoxifen resistant tumors |
| US9896466B2 (en) * | 2013-04-24 | 2018-02-20 | Kkcg Ag | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level |
| CN108495618B (zh) * | 2016-07-12 | 2019-08-16 | 冰洲石生物科技公司 | 新的化合物及其用途 |
-
2017
- 2017-07-11 CN CN201780001677.9A patent/CN108495618B/zh not_active Expired - Fee Related
- 2017-07-11 MA MA043141A patent/MA43141A/fr unknown
- 2017-07-11 CA CA3030411A patent/CA3030411A1/en not_active Abandoned
- 2017-07-11 WO PCT/US2017/041526 patent/WO2018013559A1/en not_active Ceased
- 2017-07-11 KR KR1020197003884A patent/KR20190039125A/ko not_active Ceased
- 2017-07-11 US US15/646,793 patent/US9944632B2/en active Active
- 2017-07-11 EP EP17828300.8A patent/EP3368011A4/en not_active Withdrawn
- 2017-07-11 AU AU2017297344A patent/AU2017297344A1/en not_active Abandoned
- 2017-07-11 CN CN201910655485.0A patent/CN110294788A/zh active Pending
- 2017-07-11 JP JP2019522609A patent/JP2019525955A/ja active Pending
- 2017-07-11 HK HK18116445.7A patent/HK1257296A1/zh unknown
-
2018
- 2018-01-30 US US15/883,495 patent/US10450307B2/en not_active Expired - Fee Related
-
2019
- 2019-09-04 US US16/560,178 patent/US10968212B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013056837A (ja) * | 2011-09-07 | 2013-03-28 | Japan Health Science Foundation | アポトーシス阻害タンパク質リガンド−エストロゲン受容体リガンドハイブリッド化合物並びにそれを利用したエストロゲン受容体分解誘導剤及び乳癌、子宮頚癌又は卵巣癌の予防及び治療剤 |
| US20160136230A1 (en) * | 2013-07-03 | 2016-05-19 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| US10450307B2 (en) | 2019-10-22 |
| HK1257296A1 (zh) | 2019-10-18 |
| HK1257539A1 (zh) | 2019-10-25 |
| US9944632B2 (en) | 2018-04-17 |
| CN108495618A (zh) | 2018-09-04 |
| WO2018013559A1 (en) | 2018-01-18 |
| EP3368011A1 (en) | 2018-09-05 |
| CA3030411A1 (en) | 2018-01-18 |
| MA43141A (fr) | 2018-09-05 |
| EP3368011A4 (en) | 2019-07-10 |
| US20180016269A1 (en) | 2018-01-18 |
| US20180208590A1 (en) | 2018-07-26 |
| CN108495618B (zh) | 2019-08-16 |
| US10968212B2 (en) | 2021-04-06 |
| AU2017297344A1 (en) | 2019-01-31 |
| KR20190039125A (ko) | 2019-04-10 |
| US20200024269A1 (en) | 2020-01-23 |
| CN110294788A (zh) | 2019-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10968212B2 (en) | Compounds having estrogen receptor alpha degradation activity and uses thereof | |
| US12331061B2 (en) | Compounds having BET, estrogen receptor, and androgen receptor degradation activity and uses thereof | |
| JP7662639B2 (ja) | エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用 | |
| US10696659B2 (en) | Compounds having estrogen receptor alpha degradation activity and uses thereof | |
| JP7355741B2 (ja) | ベンズアミド化合物 | |
| JP2020117510A (ja) | Nmda受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物 | |
| JP2018536658A (ja) | テトラヒドロナフタレンエストロゲン受容体モジュレーター及びその使用 | |
| US20220185798A1 (en) | Dopamine d3 receptor selective antagonists/partial agonists; method of making; and use thereof | |
| EP3774722B1 (en) | Opioid receptor modulators and products and methods related thereto | |
| EP3022201A1 (en) | Autotaxin inhibitors | |
| WO2023192430A1 (en) | Compounds for treating psychostimulant misuse | |
| HK40014926A (en) | Novel compounds and uses thereof | |
| HK1257539B (en) | Novel compounds and uses thereof | |
| US11299476B2 (en) | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | |
| US20130261133A1 (en) | Therapeutic Compounds for Protozoal and Microbial Infections and Cancer | |
| US20240374737A1 (en) | Erk5 degraders and uses thereof | |
| US20140309275A1 (en) | Sphingosine Analogs, Compositions, and Methods Related Thereto | |
| JP2023508324A (ja) | 組み合わせ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200710 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200710 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210820 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220314 |